More from GILD Q2 2026

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

Yeztugo PrEP momentum: persistency, launch mode, and guidance support

Yeztugo was described as the leading long-acting PrEP option for new patient starts and a key contributor to PrEP growth.
Management said quarterly PrEP sales exceeded $1 billion for the first time and linked the result to expanding uptake across naive and switch markets.
Company shared Yeztugo persistency data, stating more than 70% of users returned for reinjection at 6 months and extended protection to a full year.
Johanna emphasized “launch momentum” into the back half of 2026 and reaffirmed the full-year Yeztugo sales target of approximately $1 billion.
In Q&A, management attributed growth to strong uptake, HCP confidence in access/logistics, education/awareness work across communities, and persistency.

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

Financial Performance Summary

Base business sales were $7.6B, up 10% year-over-year (and strongest second-quarter growth in 3 years).
HIV sales were $5.7B, up 12% year-over-year; sequential HIV sales were up 13% (inventory build and higher average realized price).
Non-GAAP diluted EPS was -$6.75 for the quarter; excluding acquired IPR&D and nonrecurring other revenue, illustrative non-GAAP diluted EPS was $2.27.
Product gross margin was 87% (flat year-over-year) and in line with full-year guidance; non-GAAP operating margin was negative 94% due to acquired IPR&D, but ~49% excluding acquired IPR&D.
Total product sales (excluding Veklury) were $7.6B, up 10% year-over-year; sequential base business sales were up 12%.
Total product sales including Veklury were $7.6B, up 8% year-over-year and 10% sequentially; Trodelvy, Livdelzi and key HIV brands drove growth.

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

We continue to be very pleased with the progress of the launch and with second quarter sales of $232 million, up 40% sequentially and continue to target full year 2026 sales of approximately $1 billion.

Johanna Mercier

CCCAO, Gilead Sciences, Inc.

Context

Johanna discussed Yeztugo’s PrEP momentum, persistency results, and how it supports full-year guidance. Johanna tied Yeztugo’s performance to launch momentum across both naive and switch markets and emphasized growing confidence among healthcare professionals about access pathways and logistics. She also referenced the PrEP market growth rate and the company’s persistency data (>70% returning for reinjection at 6 months). She then connected these points to Yeztugo’s Q2 sales and reaffirmed the full-year target of approximately $1 billion.

More from GILD Q2 2026

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

Yeztugo PrEP momentum: persistency, launch mode, and guidance support

Yeztugo was described as the leading long-acting PrEP option for new patient starts and a key contributor to PrEP growth.
Management said quarterly PrEP sales exceeded $1 billion for the first time and linked the result to expanding uptake across naive and switch markets.
Company shared Yeztugo persistency data, stating more than 70% of users returned for reinjection at 6 months and extended protection to a full year.
Johanna emphasized “launch momentum” into the back half of 2026 and reaffirmed the full-year Yeztugo sales target of approximately $1 billion.
In Q&A, management attributed growth to strong uptake, HCP confidence in access/logistics, education/awareness work across communities, and persistency.

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

Financial Performance Summary

Base business sales were $7.6B, up 10% year-over-year (and strongest second-quarter growth in 3 years).
HIV sales were $5.7B, up 12% year-over-year; sequential HIV sales were up 13% (inventory build and higher average realized price).
Non-GAAP diluted EPS was -$6.75 for the quarter; excluding acquired IPR&D and nonrecurring other revenue, illustrative non-GAAP diluted EPS was $2.27.
Product gross margin was 87% (flat year-over-year) and in line with full-year guidance; non-GAAP operating margin was negative 94% due to acquired IPR&D, but ~49% excluding acquired IPR&D.
Total product sales (excluding Veklury) were $7.6B, up 10% year-over-year; sequential base business sales were up 12%.
Total product sales including Veklury were $7.6B, up 8% year-over-year and 10% sequentially; Trodelvy, Livdelzi and key HIV brands drove growth.

Gilead Sciences, Inc.

GILD2026 Q2Healthcare

1mo

Johanna Mercier

CCCAO, Gilead Sciences, Inc.

Context

Gilead Sciences, Inc.: Quarterly PrEP sales exceeded $1B for the first time

More from GILD Q2 2026

Gilead Sciences, Inc. 2026 Q2: Yeztugo PrEP momentum: persistency, launch mode, and guidance support

Gilead Sciences, Inc. 2026 Q2: Financial Performance summary

More from GILD Q2 2026

More from GILD Q2 2026

Gilead Sciences, Inc. 2026 Q2: Yeztugo PrEP momentum: persistency, launch mode, and guidance support

Gilead Sciences, Inc. 2026 Q2: Financial Performance summary